Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B536e08a39eb931d32bd0404730cd93e7> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B536e08a39eb931d32bd0404730cd93e7 NCIT_P378 "NCI" @default.
- B536e08a39eb931d32bd0404730cd93e7 type Axiom @default.
- B536e08a39eb931d32bd0404730cd93e7 annotatedProperty IAO_0000115 @default.
- B536e08a39eb931d32bd0404730cd93e7 annotatedSource NCIT_C78194 @default.
- B536e08a39eb931d32bd0404730cd93e7 annotatedTarget "The hydrochloride salt form of an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome." @default.